Lv22
124 积分 2024-05-15 加入
Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial
1天前
待确认
Fleischner Society Guideline Recommendations for Incidentally Detected Pulmonary Nodules and the Probability of Lung Cancer
2天前
已完结
The Society of Thoracic Surgeons (2025) Expert Consensus Document on Interventions for Screen-Detected Lung Nodules
3天前
已完结
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations
4天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
8天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
8天前
已完结
Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making
10天前
已完结
Efficacy and safety of aumolertinib/icotinib combination therapy for naive EGFR -mutant non–small-cell lung cancer patients with brain metastases: A phase I/II study
10天前
已完结
Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach
20天前
已完结
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC
25天前
已完结
皖公网安备34019202002308
